Stanisic, S., Cicchetti, A., Porta, C., Procopio, G. and Berto, P. 2018. Cost-effectiveness of cabozantinib in second-line treatment of metastatic renal cell cancer (mRCC) in Italy. Global and Regional Health Technology Assessment. 5, 1 (Jul. 2018). DOI:https://doi.org/10.33393/grhta.2018.434.